Phase I trial of targeted alpha-particle therapy with Actinium-225 ((225)Ac)-lintuzumab and low-dose cytarabine (LDAC) in patients age 60 or older with untreated acute myeloid leukemia (AML) Meeting Abstract


Authors: Jurcic, J. G.; Levy, M. Y.; Park, J. H.; Ravandi, F.; Perl, A. E.; Pagel, J. M.; Smith, B. D.; Estey, E. H.; Kantarjian, H.; Cicic, D.; Scheinberg, D. A.
Abstract Title: Phase I trial of targeted alpha-particle therapy with Actinium-225 ((225)Ac)-lintuzumab and low-dose cytarabine (LDAC) in patients age 60 or older with untreated acute myeloid leukemia (AML)
Meeting Title: 58th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 128
Issue: 22
Meeting Dates: 2016 Dec 3-6
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2016-12-02
Language: English
ACCESSION: WOS:000394452305129
PROVIDER: wos
Notes: Meeting Abstract: 4050 -- Source: Wos
MSK Authors
  1. Jae Hong Park
    132 Park
Related MSK Work